@changes_iv: thanks for this information !
Is there any more evidence needed why IMO the FDA is in bed with BigPharma? More and more people are suffering from anxiety, depression and other such disorders, such as hopelessness and despair, and the number of people has increased dramatically due to the COVID-19 pandemic.
….but read carefully what is going on:
The global anxiety disorders and depression treatment market size is projected to reach USD 13.03 billion by 2027, exhibiting a CAGR of 2.6% during the forecast period. Deterioration of mental health amid the COVID-19 pandemic will prove beneficial for this market postulates. Mental health has been one of the many casualties of the coronavirus pandemic, with anxiety, depression, and other such disorders becoming a commonplace occurrence in several parts of the world. According to a study conducted by the Boston University in September 2020, half of the adults surveyed by the researchers across the US displayed some signs of depression, such as feelings of hopelessness and failure, due to COVID-19.
Key prominent players covered in the Anxiety Disorders and Depression Treatment Market Research Report are:
Bristol-Myers Squibb (New York, U.S)
Johnson & Johnson (New Jersey, U.S)
Merck & Co. Inc. (New Jersey, U.S)
Pfizer Inc. (New York, U.S)
Eli Lilly and Company (Indiana, U.S)
AstraZeneca (Cambridge, U.K)
GlaxoSmithKline plc (Brentford, U.K)
H. Lundbeck A/S (Denmark, Europe)
and other key market players......
....they are all afraid of a drug that will bring back hope to everyone !
